HYDRAZINOPURINE COMPOUND AND TRIAZOLOPURINE COMPOUND FOR INHIBITING XANTHINE OXIDASE
申请人:Tera Stone Co., Ltd
公开号:EP3845535A1
公开(公告)日:2021-07-07
The present invention relates to a hydrazinopurine compound or triazolopurine compound represented by the general formula (wherein R1, R3, R4, R6, R8, R10, and R12 represent hydrogen atom or alkyl group; and R2, R5, R7, R9, R11, and R13 represent hydrogen atom, alkyl group, or an aryl group.), a xanthine oxidase inhibitory composition containing the abovementioned compound as an active ingredient, and a medicinal composition containing the abovementioned compound as an active ingredient, particularly a medicinal composition for preventing or treating hyperuricemia, gout, and a disease caused by hyperuricemia.
本发明涉及一种由通式(其中R1、R3、R4、R6、R8、R10和R12代表氢原子或烷基;R2、R5、R7、R9、R11和R13代表氢原子、烷基或芳基)表示的肼基嘌呤化合物或三唑嘌呤化合物,一种含有上述化合物作为活性成分的黄嘌呤氧化酶抑制剂组合物,以及一种含有上述化合物作为活性成分的药物组合物,特别是一种用于预防或治疗高血压的药物组合物。)、含有上述化合物作为活性成分的黄嘌呤氧化酶抑制剂组合物,以及含有上述化合物作为活性成分的药物组合物,特别是用于预防或治疗高尿酸血症、痛风和由高尿酸血症引起的疾病的药物组合物。